| Identification | More | [Name]
Proparacaine hydrochloride | [CAS]
5875-06-9 | [Synonyms]
2-diethylaminoethyl 3-amino-4-propoxy-benzoate hydrochloride
PROPARACAINE HCL
PROPARACAINE HYDROCHLORIDE
3-amino-4-propoxybenzoicacid2-(diethylamino)ethylesterhydrochloride
alcaine
benzoicacid,3-amino-4-propoxy-,2-(diethylamino)ethylester,hydrochloride
benzoicacid,3-amino-4-propoxy-,2-(diethylamino)ethylester,monohydrochlorid
beta-(diethylamino)ethyl3-amino-4-n-propoxybenzoatehydrochloride
chibro-heracaine
keracaine
ophthain
ophthainehydrochloride
ophthetic
ProxymetacaineHCL2-CHLORO-9-(2'-DEOXY-2'-FLUORO-B-D-ARABINOFURANOSYL)ADENINE
PROXYMETACAINE(2-DIETHYLAMINOETHYL-3-AMINO-4-PROPOXYBENZOATE HYDROCHLORIDE)
PROXYMETACAINEHYDROCHLORIDE/PROPARACAINE | [EINECS(EC#)]
227-541-7 | [Molecular Formula]
C16H27ClN2O3 | [MDL Number]
MFCD00083467 | [Molecular Weight]
330.85 | [MOL File]
5875-06-9.mol |
| Chemical Properties | Back Directory | [Melting point ]
182.0-183.3° | [storage temp. ]
Inert atmosphere,Store in freezer, under -20°C | [solubility ]
Chloroform (Slightly), Methanol, Water | [form ]
Solid | [pka]
3.2(at 25℃) | [color ]
White to Off-White | [λmax]
300nm(MeOH)(lit.) | [Merck ]
14,7807 | [InChI]
InChI=1S/C16H26N2O3.ClH/c1-4-10-20-15-8-7-13(12-14(15)17)16(19)21-11-9-18(5-2)6-3;/h7-8,12H,4-6,9-11,17H2,1-3H3;1H | [InChIKey]
BFUUJUGQJUTPAF-UHFFFAOYSA-N | [SMILES]
C(OCCN(CC)CC)(=O)C1=CC=C(OCCC)C(N)=C1.[H]Cl | [CAS DataBase Reference]
5875-06-9(CAS DataBase Reference) |
| Safety Data | Back Directory | [Hazard Codes ]
Xn | [Risk Statements ]
R20/21/22:Harmful by inhalation, in contact with skin and if swallowed .
R36:Irritating to the eyes.
R43:May cause sensitization by skin contact. | [Safety Statements ]
S26:In case of contact with eyes, rinse immediately with plenty of water and seek medical advice .
S36:Wear suitable protective clothing . | [WGK Germany ]
3
| [RTECS ]
DG3065000
| [HS Code ]
2922504500 |
| Hazard Information | Back Directory | [Description]
Proparacaine Hydrochloride is the hydrochloride salt form of proparacaine, a benzoic acid derivative with local anesthetic property. Proparacaine hydrochloride stabilizes the neuronal membrane by binding to and inhibiting voltage-gated sodium channels, thereby inhibiting sodium ion influx required for the initiation and conduction of impulses within the neuronal cell, and resulting in a loss of sensation. | [Uses]
Anesthetic;Neuronal conductance inhibitor | [Brand name]
Alcaine (Alcon); Ophthetic (Allergan); Paracaine (Optopics). | [Clinical Use]
Proparacaine Hydrochloride Ophthalmic Solution is indicated for topical anesthesia in ophthalmic practice. | [Side effects]
Occasional temporary stinging, burning and conjunctival redness may occur with the use of proparacaine. A rare, severe, immediate-type, apparently hyperallergic corneal reaction characterized by acute, intense and diffuse epithelial keratitis, a gray, ground glass appearance, sloughing of large areas of necrotic epithelium, corneal filaments and sometimes iritis with descemetitis has been reported. Allergic contact dermatitis from proparacaine with drying and fissuring of the fingertips has been reported. | [storage]
Store at -20°C | [Mode of action]
The mechanism of action of proparacaine hydrochloride is to reduce the instantaneous permeability of neurons to sodium, stabilize the nerve cell membrane, and prevent the generation and conduction of nerve electrical impulses, thereby producing anesthesia.Likely inhibits epithelial voltage gated sodium channels like other local anesthetics. | [References]
1. Identification, synthesis and structural confirmation of process-related impurities in proparacaine hydrochloride. DOI:10.1016/j.jpba.2020.113497
2. https://pi.bausch.com/globalassets/pdf/PackageInserts/Pharma/Rx-Generics/Proparacaine-HCl-Ophthalmic-Solution.pdf
3. Imming P., Sinning C., Meyer A. Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct; 5(10):821-34. DOI:10.1038/nrd2132
4. T., Levent T., Inci M.A. Toxic keratopathy associated with abuse of topical anesthetics and amniotic membrane transplantation for treatment. Int J Ophthalmol. 2015; 8(5): 938–944. DOI:10.3980/j.issn.2222-3959.2015.05.15
5. Proparacaine Hydrochloride Topical Drop and Intracameral 0.5% Lignocaine for Phacotrabeculectomy in Patients with Primary Open Angle Glaucoma DOI:10.4103/0974-9233.134669
6. https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=447a2a64-0507-4fe8-bb44-cc36c3916151&type=display |
|
|